Pulsenmore publishes investor presentation on FDA-cleared home-use maternal ultrasound platform

Reuters03-30

<a href="https://laohu8.com/S/PLSM">Pulsenmore</a> publishes investor presentation on FDA-cleared home-use maternal ultrasound platform

Pulsenmore highlighted FDA De Novo clearance for its home-use maternal ultrasound system in Nov. 2025, positioning it for U.S. market entry tied to 3.6 million annual deliveries.
Platform metrics showed more than 220,000 patient scans completed in four years, with 98.1% deemed suitable for clinical evaluation.
U.S. revenue model outlined 60% from single-pregnancy devices priced around USD 1,000, with 40% from recurring clinician-dashboard subscriptions.
Strategic funding totaled USD 90 million to date, including a USD 21 million investment from GE HealthCare.
Clalit partnership expanded to 45,000 devices ordered cumulatively, alongside a USD 4.5 million IVF-related contract in Israel.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulsenmore Ltd. published the original content used to generate this news brief on March 30, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2623348887?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-30 20:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623348887","market":"us","top_or_hot":-1,"title":"Pulsenmore publishes investor presentation on FDA-cleared home-use maternal ultrasound platform","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/PLSM\">Pulsenmore</a> publishes investor presentation on FDA-cleared home-use maternal ultrasound platform\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Pulsenmore highlighted FDA De Novo clearance for its home-use maternal ultrasound system in Nov. 2025, positioning it for U.S. market entry tied to 3.6 million annual deliveries.\n        </li>\n<li>\n          Platform metrics showed more than 220,000 patient scans completed in four years, with 98.1% deemed suitable for clinical evaluation.\n        </li>\n<li>\n          U.S. revenue model outlined 60% from single-pregnancy devices priced around USD 1,000, with 40% from recurring clinician-dashboard subscriptions.\n        </li>\n<li>\n          Strategic funding totaled USD 90 million to date, including a USD 21 million investment from GE HealthCare.\n        </li>\n<li>\n          Clalit partnership expanded to 45,000 devices ordered cumulatively, alongside a USD 4.5 million IVF-related contract in Israel.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulsenmore Ltd. published the original content used to generate this news brief on March 30, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pulsenmore publishes investor presentation on FDA-cleared home-use maternal ultrasound platform</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPulsenmore publishes investor presentation on FDA-cleared home-use maternal ultrasound platform\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-30 20:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/PLSM\">Pulsenmore</a> publishes investor presentation on FDA-cleared home-use maternal ultrasound platform\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Pulsenmore highlighted FDA De Novo clearance for its home-use maternal ultrasound system in Nov. 2025, positioning it for U.S. market entry tied to 3.6 million annual deliveries.\n        </li>\n<li>\n          Platform metrics showed more than 220,000 patient scans completed in four years, with 98.1% deemed suitable for clinical evaluation.\n        </li>\n<li>\n          U.S. revenue model outlined 60% from single-pregnancy devices priced around USD 1,000, with 40% from recurring clinician-dashboard subscriptions.\n        </li>\n<li>\n          Strategic funding totaled USD 90 million to date, including a USD 21 million investment from GE HealthCare.\n        </li>\n<li>\n          Clalit partnership expanded to 45,000 devices ordered cumulatively, alongside a USD 4.5 million IVF-related contract in Israel.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulsenmore Ltd. published the original content used to generate this news brief on March 30, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL9f3q6B:1","article_id":"2623348887","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2623348887","pubTimestamp":1774874966,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Pulsenmore highlighted FDA De Novo clearance for its home-use maternal ultrasound system in Nov. 2025, positioning it for U.S. market entry tied to 3.6 million annual deliveries.Platform metrics showed more than 220,000 patient scans completed in four years, with 98.1% deemed suitable for clinical evaluation.U.S. revenue model outlined 60% from single-pregnancy devices priced around USD 1,000, with 40% from recurring clinician-dashboard subscriptions.Strategic funding totaled USD 90 million to date, including a USD 21 million investment from GE HealthCare.Clalit partnership expanded to 45,000 devices ordered cumulatively, alongside a USD 4.5 million IVF-related contract in Israel.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulsenmo","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4082":"医疗保健设备","GEHC":"GE HEALTHCARE TECHNOLOGIES INC","LU0124676726.USD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (USD) ACC","LU0689626769.HKD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (HKD) ACC","BK4588":"碎股"},"translate_title":"Pulsenmore发布有关FDA批准的家用孕产妇超声平台的投资者演示文稿","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GEHC":0.9},"content_text":"Pulsenmore publishes investor presentation on FDA-cleared home-use maternal ultrasound platform\n    \n\n\n          Pulsenmore highlighted FDA De Novo clearance for its home-use maternal ultrasound system in Nov. 2025, positioning it for U.S. market entry tied to 3.6 million annual deliveries.\n        \n\n          Platform metrics showed more than 220,000 patient scans completed in four years, with 98.1% deemed suitable for clinical evaluation.\n        \n\n          U.S. revenue model outlined 60% from single-pregnancy devices priced around USD 1,000, with 40% from recurring clinician-dashboard subscriptions.\n        \n\n          Strategic funding totaled USD 90 million to date, including a USD 21 million investment from GE HealthCare.\n        \n\n          Clalit partnership expanded to 45,000 devices ordered cumulatively, alongside a USD 4.5 million IVF-related contract in Israel.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulsenmore Ltd. published the original content used to generate this news brief on March 30, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2623348887","isCrawlerRequest":true}